+91-8668442535

Solid Tumor Cancer Treatment Market By Indication (Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Surgical Procedures) - Growth, Future Prospects, And Competitive Analysis, 2019 - 2027

Industry Outlook

The solid tumor cancer treatment market is set to grow from US$ 121.3 billion in 2018 to US$ 424.6 billion by 2027 at a compound annual growth rate (CAGR) of 15.0% during the forecast period from 2019 to 2027. According to the latest statistics presented by the World Health Organization (WHO) in 2018, approximately 9.6 million people are estimated to die due to cancer; they also claim that 30 to 50% of cancer can be prevented with early diagnosis and an effective treatment regimen.

Hormonal imbalance and an unhealthy lifestyle increase the risk of breast cancer in the female population worldwide

Breast cancer is currently leading the indications segment of the solid tumor cancer treatment market. The key parameters responsible for its high prevalence rate in the female population worldwide are hormonal imbalance during the menstrual cycle of women, an unhealthy lifestyle, and low or no breastfeeding during a woman's lifetime. The prevalence rate of lung cancer has seen a substantial rise in the last two decades, owing to an increasing number of cigarette smokers globally and a significant rise in air pollution.

Availability of a generic version at an affordable cost makes chemotherapy popular in cancer treatment

Chemotherapy is presently the largest therapy segment in the solid tumor cancer treatment market. The major factor that makes it popular in cancer treatment is its availability in a generic form at an affordable cost. They are used in combination to gain excellent results in solid tumor cancer treatment. In a span of two decades, biologics such as immunotherapy and targeted therapy have gained tremendous popularity in the treatment of solid tumor cancer. Minimal side effects, excellent therapeutic efficacy, and a favorable reimbursement scenario drive its market growth for the treatment of solid tumor cancers.

Rising prevalence of cancer and domicile of key players together drive the market growth in the North American region

North America currently represents 33.6% of the regional market for solid tumor cancer treatment. The primary factor responsible for its market dominance is the rising prevalence of cancer. According to the latest statistics brought forward by the Center for Disease Control and Prevention (CDC), in a span of 10 years from 2010-2020 in the U.S., the number of new cancer cases will rise by 24% in men, amounting to 1 million cases annually, and by 21% in women, approximately 900,000 cases per year.

The domicile of major players, such as AstraZeneca, Merck & Co., Inc., Amgen, Inc., etc., will further bolster market growth in the region. Europe accounts for 30.2% of the market share on account of the supportive regulatory environment provided by the European Medical Agency (EMA) for the development and sale of pharmacological medicines used in solid tumor cancer treatment. Favorable reimbursement scenarios further consolidate the market's growth. Asia Pacific, with a share of 19.5%, will register good growth during the forecast period owing to rising public health awareness regarding cancer and its treatment and developing healthcare infrastructure.

Historical and Forecast Period

This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by indication, therapy, and geography.

Pharmaceutical companies spearheading the solid tumor cancer treatment market are AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol-Myers Squibb & Company, Eli Lilly & Company, F. Hoffmann-La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Olympus Medical Systems.

Key questions are answered in this report.

  • Which are the major biopharmaceutical companies actively providing medicines for the treatment of solid tumor cancer?
  • Which organic and inorganic market growth strategies are being considered for performing market assessments?
  • What are the disease etiology and prevalence rate of common types of cancer worldwide?
  • What does biologics consist of, and what will be its CAGR during the growth period?
  • What is the market size in developed regions such as North America and Europe?

Frequently Asked Questions:

The market for Solid Tumor Cancer Treatment Market is expected to reach US$ 424.6 Bn by 2027.

The Solid Tumor Cancer Treatment Market is expected to see significant CAGR growth over the coming years, at 15.0%.

The report is forecasted from 2019-2027.

The base year of this report is 2018.

AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol-Myers Squibb & Company, Eli Lilly & Company, F. Hoffmann-La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2019
Category:  Pharmaceuticals
Report ID:   59822
Report Format:   PDF
Pages:   120
Rating:    4.2 (69)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support